Neurotechnology company announces treatment-resistant depression as its first clinical focus and launches online registry to support recruitment and future clinical research

Grey Matter Neurosciences today confirmed the appointment of industry veteran, Tom Wilder, to its Board of Directors.
With great enthusiasm, Grey Matter Neurosciences today announced the appointment of Josh Richmond as Vice President, Research and Development.